The short version of Synthetic peptide fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-06-07 and is reviewed periodically as new material appears.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
| Property | Value | Notes |
|---|---|---|
| Main study model | Rodents, rats and mice | Underpins most of the published data |
| Common routes in studies | Subcutaneous, intraperitoneal, oral | Varies with the experimental design |
| Common analytical method | Reversed-phase HPLC, LC-MS | Used for identity and purity checks |
| Human evidence base | Small | Few trials reported, with limited findings |
| Regulatory status | Varies by jurisdiction | Not an approved medicine in most places |
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
== Role in wound healing == HB-EGF is the predominant growth factor in the epithelialization required for cutaneous wound healing. The mitogenic and migratory effects of HB-EGF on keratinocytes and fibroblasts promotes dermal repair and angiogenesis necessary for wound healing and is a major component of wound fluids. HB-EGF displays target cell specificity during the early stages of wound healing being released by macrophages, monocytes, and keratinocytes. HB-EGF cell surface binding to heparan sulfate proteoglycans enhances mitogen promoting capabilities increasing the rate of skin wound healing, decreasing human skin graft healing times, and promotes rapid healing of ulcers, burns, and epidermal split thickness wounds.
=== Mechanical engineer === In 1912, Jones moved to Hallock, Minnesota, where he worked as a mechanic on a 50,000-acre (200 km2) farm. The farm was owned by James J. Hill, who was also owner of the Great Northern Railroad. Jones' proximity to Hill and the railroad facilitated his education in electricity and steam locomotive engines. Jones lived there for more than 20 years and would later say in a newspaper article that Hallock was a place "where a man … [was] judged more on his character and ability than on the color of his skin." He was locally known as "Casey" due to a remark by a railroad engineer he met while working at Hill Farm (see also Casey Jones). Jones received his engineering license at age 20. He later upgraded his license to the highest grade.
The company's continued presence in Russia stands in stark contrast to the actions of many of its Western counterparts, who have pulled out or scaled down their operations to align with global sanctions and the broader call for economic isolation of Russia. As the conflict in Ukraine rages on, Dr. Reddy's decision to remain in Russia raises serious concerns about the ethical implications of doing business with a country under international sanctions, while the rest of the world seeks to hold Russia accountable for its actions. Other viewpoints, particularly those outside the European and American centric western viewpoint, take the position that denying life saving pharmaceutical treatment by seeking to stop the flow of pharmaceutical goods to the common people in those countries whose actions are perceived as hostile, violent and inappropriate, such as Russia, is a deeply immoral act, and that by continuing to provide lifesaving medication to everyday citizens who have no connection to their government's foreign policy Dr. Reddy is acting in a deeply ethical way.
Treponema pallidum was first microscopically identified in syphilitic chancres by Fritz Schaudinn and Erich Hoffmann at the Charité in Berlin in 1905. Historically, this bacterium was identified in the clinical laboratory through visualization in dark-field microscopy. This bacterium can be detected with special stains, such as the Dieterle stain. T. pallidum is also detected by serology, including nontreponemal VDRL, rapid plasma reagin, treponemal antibody tests (FTA-ABS), T. pallidum immobilization reaction, and syphilis TPHA test.
Gish's debating opponents said that he used a rapid-fire approach during a debate, presenting arguments and changing topics quickly. Eugenie Scott, executive director of the National Center for Science Education, dubbed this approach the "Gish gallop", describing it as "where the creationist is allowed to run on for 45 minutes or an hour, spewing forth torrents of error that the evolutionist hasn't a prayer of refuting in the format of a debate". She also criticized Gish for failing to answer objections raised by his opponents. However, Gish said a similar thing about his debate opponents, especially Kenneth Miller. Gish accused Miller of using spread debating, i.e. speaking very fast and bringing up so many points that there was no chance to answer them all. Gish was also criticized for using a standardized presentation during debates. While undertaking research for a debate with Gish, Michael Shermer noted that Gish re-used similar openings, assumptions about his opponent, slides, and even jokes. For example, during the debate, Gish attempted to prove that Shermer was indeed an atheist and therefore immoral, even though Shermer said he was not an atheist and was willing to accept the existence of a divine creator. Massimo Pigliucci, who debated Gish five times, said that Gish ignored evidence contrary to his religious beliefs. Robert Schadewald accused Gish of stonewalling arguments with fabricated data.
Sources: en.wikipedia.org
==== Trends ==== In data from the US Drug Abuse Warning Network, mentions of hazardous or harmful use of pethidine declined between 1997 and 2002, in contrast to increases for fentanyl, hydromorphone, morphine, and oxycodone. The number of dosage units of pethidine reported lost or stolen in the US increased 16.2% between 2000 and 2003, from 32,447 to 37,687.
=== Legal status === Treosulfan was authorized for medical use in the European Union in June 2019, and approved for medical use in the United States in January 2025. The US Food and Drug Administration granted orphan drug designation to treosulfan in 1994, for the treatment of ovarian cancer; and in 2015, for conditioning treatment prior to hematopoietic stem cell transplantation in malignant and non-malignant diseases in adults and pediatric patients. In February 2004, orphan designation (EU/3/04/186) was granted by the European Commission to medac Gesellschaft fuer klinische Spezialpräparate mbH, Germany, for treosulfan for the conditioning treatment prior to haematopoietic progenitor cell transplantation.
=== United States === The Centers for Disease Control and Prevention reported that 2.8 million cases of antibiotic resistance have been reported. However, in 2019 overall deaths from antibiotic-resistant infections decreased by 18% and deaths in hospitals decreased by 30%. The COVID pandemic caused a reversal of much of the progress made on attenuating the effects of antibiotic resistance, resulting in more antibiotic use, more resistant infections, and less data on preventive action. Hospital-onset infections and deaths both increased by 15% in 2020, and significantly higher rates of infections were reported for 4 out of 6 types of healthcare associated infections.
The Victor Babeș Clinical Hospital for Infectious Diseases and Pneumophthisiology (Romanian: Spitalul Clinic de Boli Infecțioase și Pneumoftiziologie „Victor Babeș”) was founded in 1925 in the Green Forest of Timișoara as the only infectious diseases hospital in western Romania. It bears the name of Romanian pathologist Victor Babeș since 1952.
=== Loss of solubility === When proteins are folded, they fold so as to keep their hydrophobic parts on the inside (away from water) and their hydrophilic parts on the outside (contacting the water). This makes them soluble enough not to precipitate. However, when denatured the surface of the protein is partly hydrophobic and partly hydrophilic (as it no longer has an "inside" in which to hide the hydrophobic parts), causing it to become insoluble in water. The hydrophobic parts of the denatured proteins stick together, forming a network (gel): this is called coagulation. The coagulation of denatured proteins is the reason eggs solidify when cooked. When acid is added to milk, the protein casein denatures and coagulates (with fat and water inclusions from the milk) into curds, the first step in making cheese; although milk can also be made to curdle (i.e. casein to coagulate) by other methods, for example the addition of enzymes like chymosin.
Sources: en.wikipedia.org
A 2009 multisite randomized controlled study found no benefit and some adverse effects in autistic children from citalopram, raising doubts about whether SSRIs are effective for treating repetitive behavior in children with autism. Some research suggests citalopram interacts with cannabinoid protein-couplings in the rat brain, and this is put forward as a potential cause of some of the drug's antidepressant effects.
First line treatment for metastatic breast cancer: the MARIANNE study compares taxane (docetaxel or paclitaxel) plus trastuzumab vs T-DM1 vs T-DM1 plus pertuzumab as first-line treatment for people with HER2 positive unresectable locally advanced or metastatic breast cancer; On 19 December 2014, Roche reported the results of the MARIANNE study. Neither Kadcyla-containing treatment significantly improved progression-free survival compared to Herceptin and chemotherapy. a phase III trial for HER2+ gastric cancer compares T-DM1 to physician's choice of taxane (docetaxel or paclitaxel). On 22 October 2015, Roche and co-developer ImmunoGen disclosed that trastuzumab emtansine had failed to meet its primary endpoint in the Phase II/III GATSBY trial investigating the second line treatment of HER2-positive advanced gastric cancer. the TH3RESA study is comparing T-DM1 vs treatment of physician's choice for people with HER2 positive metastatic breast cancer previously treated with trastuzumab and lapatinib. Interim results for TH3RESA suggest a doubling of progression-free survival from three months to six months.
Synthetic Fe–S clusters are laboratory-prepared coordination compounds or chains, often designed to mimic the structural, electronic, or chemical properties of biological Fe–S clusters. Roussin's black anion, [Fe4S3(NO)7]−, described in 1858, is the first synthetic Fe-S cluster. It has the geometry of an incomplete cubane-type cluster with C3v symmetry. The dark color of the complex is attributed to a number of charge-transfer interactions. Since the 1970s, many of these Fe-S clusters have been described. A key property of Fe–S clusters is their ability to undergo redox.
=== Citizens' band and personal radio services === Citizens' band radio is allocated in many countries, using channelized radios in the upper HF part of the spectrum (around 27 MHz). It is used for personal, small business and hobby purposes. Other frequency allocations are used for similar services in different jurisdictions, for example UHF CB is allocated in Australia. A wide range of personal radio services exist around the world, usually emphasizing short-range communication between individuals or for small businesses, simplified license requirements or in some countries covered by a class license, and usually FM transceivers using around 1 watt or less.
retrogene A gene or other DNA sequence which has arisen in a genome by the stable integration of the genetic material of a retrovirus, e.g. by the reverse transcription of viral RNA and the subsequent insertion of the resulting DNA fragments into the host cell's genomic DNA. These endogenous viral elements can then be replicated along with the host's own genes and thus persist indefinitely in the host genome, and in many cases retain the ability to produce functional viral proteins from this latent state, by which they may continue to copy, excise, and/or transpose themselves.
Sources: en.wikipedia.org
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.
They are best described as working hypotheses. Supporting data come mainly from cell cultures and animal tissue, using markers such as growth factors and inflammatory signals. Confirmatory human studies have not been reported.
Status depends on the country. In some places it is treated as a research chemical available without a prescription, while elsewhere it falls under prescription or controlled rules. It holds no general marketing approval as a therapeutic product.
The letters BPC stand for body protection compound. The number 157 refers to a specific fragment designation from early work on gastric proteins. The full name is a label for a synthetic fifteen-amino-acid peptide rather than a naturally isolated drug.